and cell therapies. the company’s platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. its lead biologic product candidate is anktiva, an fda-approved immunotherapy in combination with bacillus calmette-guérin...